VX-548, designed as an alternative to opioids in treating acute pain, posted mixed trial results. Some analysts are questioning the commercial viability of Vertex’s drug.
Sagimet’s liver drug impresses in year-long NASH trial
The pill from Sagimet Biosciences led to a statistically significant treatment effect in patients with NASH and moderate-to-severe liver fibrosis at the 52-week mark, data show.
Ionis’ long-term HAE drug lowered attack rates, topline Phase 3 results show
The results from Ionis suggest the drug, donidalorsen, led to a statistically significant reduction in the rate of HAE attacks in patients treated every four or eight weeks.
GSK, the Tigerlily Foundation want to diversify clinical trials
Positive results from the head-to-head combination trial set the stage for GSK blood cancer drug Blenrep’s possible return to the U.S. multiple myeloma market.
MorphoSys still plans to file myelofibrosis drug despite mixed Phase 3 results